Palmitoylation regulates norepinephrine transporter trafficking and expression and is potentially involved in the pathogenesis of postural orthostatic tachycardia syndrome
Abstract
Postural orthostatic tachycardia syndrome (POTS) is an adrenergic signaling disorder characterized by excessive plasma norepinephrine, postural tachycardia, and syncope. The norepinephrine transporter (NET) modulates adrenergic homeostasis via reuptake of extracellular catecholamines and is implicated in the pathogenesis of adrenergic and neurological disorders. Previous research has outlined that NET activity and trafficking is modulated via reversible post-translational modifications like phosphorylation and ubiquitylation. S-palmitoylation, or the addition of a 16-carbon saturated fatty acid, is another post-translational modification responsible for numerous biological mechanisms. In this study, we reveal that NET is dynamically palmitoylated and inhibition of this modification with the palmitoyl acyltransferase (DHHC) inhibitor, 2-bromopalmitate (2BP), results in decreased NET palmitoylation within 90 min of treatment. This result was followed closely with a reduction in transport capacity, cell surface, and total cellular NET expression after 120 min of treatment. Increasing 2BP concentrations and treatment time revealed a nearly complete loss of total NET protein. Co-expression with individual DHHCs revealed a single DHHC enzyme, DHHC1, promoted WT hNET palmitoylation and elevated NET protein levels. The POTS associated NET mutant, A457P, exhibits dramatically decreased transport capacity and cell surface levels which we have confirmed in the current study. In an attempt to recover A457P NET expression we co-expressed the A457P variant with DHHC1 to drive expression as seen with the WT protein but instead saw an increase in NET N-terminal immuno-detectable fragments. Further investigation of A457P NET palmitoylation and surface expression is necessary, but our preliminary novel findings reveal palmitoylation as a mechanism of NET regulation and suggest that dysregulation of this process may contribute to the pathogenesis of POTS.
02 /Specification & Classification
Click any tag to browse matching papers- Citations
- 2
- Organism
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Palmitoylation regulates human serotonin transporter activity, trafficking, and expression and is modulated by escitalopram
Christopher R. Brown, James D. Foster·ACS Chemical NeurosciencePeer-reviewed·Aug 30, 2023
- Transient Suppression of Dopamine Transporter Palmitoylation by Methamphetamine: Implications for Transport Regulation
Moriah J. Hovde, Danielle E. Bolland, … Roxanne A. Vaughan·The FASEB JournalPeer-reviewed·Oct 30, 2025
- The palmitoyl acyltransferase DHHC5 mediates beta-adrenergic signaling in the heart by targeting Gα proteins and G protein-coupled receptor kinase 2
J. J. Chen, A. N. Marsden, … D. Boehning·bioRxiv·Jul 17, 2018
- Chemoselective Bioconjugation Reveals Norepinephrinylation (NEylation) as a Widespread Post-Translational Modification in Cells
Lin Zeng, Xingyu Ma, … Qingfei Zheng·bioRxiv·Aug 10, 2026
- Dysregulation of N-terminal acetylation causes cardiac arrhythmia and cardiomyopathy
D. Yoshinaga, R. Feng, … V. J. Bezzerides·bioRxiv·Jul 2, 2023
- Stress-induced changes in the S-palmitoylation and S-nitrosylation of synaptic proteins
Monika Zaręba-Kozioł, Anna Bartkowiak-Kaczmarek, … Jakub Włodarczyk·Molecular & Cellular ProteomicsPeer-reviewed·Jul 16, 2019